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ABSTRACT
Objectives: To evaluate the current needs for joint
surgery in patients with psoriatic arthritis (PsA).
Methods: The patient database at the Rheumatology
Department of the University Hospitals Leuven, was
cross-sectionally analysed using demographic, medical,
laboratory, radiological and surgical data of 269
patients with PsA. Patients were grouped by the
presence or absence of orthopaedic surgery and
compared for gender, age, mean health assessment
questionnaire (HAQ) score, current medication and
disease duration. The data were assessed using
descriptive statistics and Student’s t-tests.
Results: Overall 48.33% of the patients underwent 1
or more orthopaedic surgeries at some point of time.
A total of 280 surgical interventions were flagged in
the database, including both joint sacrificing and non-
joint sacrificing procedures. Mean disease duration±SD
at the time of surgery was 1.58 years±12.05. Age of
the patients with surgeries was 54.13 years±11.03 SD
and not different from those without surgeries
(53.73 years±12.81 SD; p=0.78). 41.54% of the
patients underwent a single surgery while 58.46% had
multiple surgeries. A significant difference in the mean
HAQ score was observed among the patients with and
without surgeries (p<0.001). Of all the surgeries
63.92% were performed after diagnosis whereas
36.07% were performed before a diagnosis of PsA was
made. Among the surgeries performed before
diagnosis 40.59% were arthroscopies including 9.90%
of diagnostic arthroscopies.
Conclusions: The number of surgical interventions
has significantly increased in patients with PsA
compared with historical cohorts even with a relatively
shorter disease duration. There was a significant
difference in HAQ score between the patients with or
without surgeries.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂam-
matory joint disease associated with psoria-
sis.1 2 The estimated prevalence of PsA
around the globe varies from 0.02% to 1%
whereas its prevalence in patients with
psoriasis ranges between 6% and 48%.1 3 4
Structural damage revealed by X-rays
observed in the joints of the patients with
PsA appears of a similar magnitude and
impact as seen in the patients with rheuma-
toid arthritis (RA).5 Structural damage in
PsA is not limited to cartilage loss and bone
erosions as in RA, but some patients with PsA
also show speciﬁc features of joint remodel-
ling with new bone formation potentially
leading to joint ankylosis. Severe osteolysis
clinically presenting as arthritis mutilans is
also a speciﬁc feature of this disease.5–9 PsA
was for long considered a relatively benign
disorder, but it has become clear that 40–
60% of all the patients will develop erosive
arthritis, loss of joint architecture and asso-
ciated loss of function clearly positioning PsA
as a major health concern.1 4 10 11
Key messages
What is already known about this subject?
▸ Psoriatic arthritis (PsA) is a chronic inflamma-
tory joint disease. Many patients with PsA
develop destructive arthritis with bone erosions
and loss of joint architecture often leading to
loss of joint function.
What does this study add?
▸ The study shows an increase in the number of
surgical interventions in patients with PsA irre-
spective of the disease duration.
▸ Higher HAQ score in patients who underwent
surgeries reflects that the impact of disease on
patients who require surgery is higher.
How might this impact on clinical practice?
▸ The study shows a high prevalence of joint
surgery in this cohort. Early diagnosis and
aggressive management of PsA from the very
beginning to slow down the disease progression
may reduce the risk of surgical interventions
and provide an opportunity to improve the
quality of life in these patients.
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Current treatment strategies, and in particular speciﬁc
targeting of tumour necrosis factor (TNF), are relatively
effective in controlling inﬂammation and also signiﬁ-
cantly inhibit radiographic progression of disease,
improve joint function and disease outcome by prevent-
ing joint erosions and destruction.12–15 However, in
advanced cases, damage is only rarely undone and
patients may require surgery to maintain or restore joint
function at some point in their disease course.4 Limited
literature on surgical needs and management of patients
with PsA is available, and little is known about the
associated outcomes. In addition, most studies have
been reported before the widespread use of anti-TNF
strategies.
Zangger et al reported earlier on surgery in a cohort
study of 444 patients with PsA suggesting that the prob-
ability of having an orthopaedic intervention increased
with the disease duration. The patients in this study had
their ﬁrst surgery at an average disease duration of
13.9 years, and no differences were found in the base-
line characteristics and functional outcome parameters
between the surgical and the non-surgical group. Out of
all the patients with PsA reviewed in this cohort, only
7% of the patients required surgical management to
restore function with hip arthroplasty being the most
common procedure performed followed by the knee
and hand surgery.16 Few years later, Zangger et al17 as
well as Michet et al18 showed that among all the patients
with PsA undergoing surgery, a polyarticular clinical
disease pattern seems to predominate, with hip and
knee interventions again being the most common surgi-
cal procedures performed. The study of Michet et al18
also showed that out of 504 patients with PsA, 32
(6.30%) required hip arthroplasty in the early years of
the disease in contrast to the observations of Zangger
et al. Belsky and colleagues reported that out of 105
patients with PsA included in their study, 25 (24%)
underwent hand surgeries due to severe deformities. Of
interest is the incidence of postsurgery infections in this
cohort, which appeared high and minimal postsurgical
improvement was noted.19
As most of the available data on orthopaedic surgery
in patients with PsA are more than a decade old and
therefore deal with patients with PsA for whom only
limited medical treatment options were available, we
performed a new cross-sectional analysis of orthopaedic
interventions in our PsA patient cohort, thereby includ-
ing a large population of anti-TNF treated patients.
METHODS
Study population
A cross-sectional analysis was carried out using the
SPAR (Spondyloarthritis Registry) database at the
Rheumatology Department of the University Hospitals
Leuven, which contains the prospective demographic,
medical, laboratory, radiological and surgical data of 269
patients with PsA in clinical follow-up from year 2000 to
2014. Patients were classiﬁed as having PsA based on the
clinical assessment and ClASsiﬁcation criteria for
Psoriatic ARthritis (CASPAR) criteria.20 The SPAR data-
base includes patients with all forms of disease type, sever-
ity, duration, treatment and activity, thereby representing
a full spectrum of PsA as seen in a referral centre with a
secondary regional and tertiary academic function. All
the patients with PsA who were registered in the database
and able and willing to give informed consent were
included in this study. Ethical approval for the data col-
lection was obtained from the Ethical Committee for
Clinical Research at the University Hospitals Leuven.
Surgical data
The surgical data registered in the database were used
for this analysis. Surgical data were recorded prospect-
ively, and surgeries performed before diagnosis and
entry into the database were retrospectively registered
based on the patient’s clinical history and medical
records. All the musculoskeletal surgeries registered in
the database were included in the analysis. One
hundred and thirty patients out of 269 patients with PsA
registered in the database had one or more orthopaedic
surgeries related to PsA. Surgeries include both joint sac-
riﬁcing (ankle prosthesis, arthrodesis, hip prosthesis,
knee prosthesis, shoulder prosthesis and spine pros-
thesis) and non-joint sacriﬁcing procedures (arthro-
scopic synovectomy, carpal tunnel syndrome (CTS),
diagnostic arthroscopy, discectomy, meniscus surgery
and others). The subcategory others include surgeries of
feet, hand, spine, knee, wrist, shoulder, elbow, cheek,
etc. As it is an exploratory study, hence all the registered
musculoskeletal surgeries were included in the study.
The date and year of the surgical interventions were also
recorded in the database.
Statistical analysis
Basic demographic data were analysed after the database
lock in December 2014. Patients were grouped depend-
ing on whether they had surgery or not. Each group was
further analysed and compared on the basis of age,
gender, current medication, mean HAQ score and
mean disease duration at surgery. The HAQ scores
recorded on the last visit for all the patients before the
data analysis were used for the comparison. The data on
the orthopaedic surgeries were also grouped based on
whether the surgery was performed before or after the
diagnosis of PsA and before or after the inclusion in the
SPAR database. Data are presented as means+SD unless
indicated otherwise. Groups were compared with χ2 test
or Student’s t-test/Mann-Whitney U test where appropri-
ate. A signiﬁcance level of 0.05 was used. Statistical ana-
lysis was performed using SPSS V.22.
RESULTS
A total of 269 patients with PsA were registered in the
database at the time of the database lock. The general
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characteristics of the PsA population are shown in
table 1. Of the 269 patients, 60.96% were males and
38.66% were females with a mean age of 53.94 years.
Almost 49% of the patients had a positive family history
of psoriasis, whereas 62.82% of these patients also had
skin involvement with a mean Psoriasis Area Severity
Index (PASI) score±SD of 1.77±5.05.
One hundred and thirty (48.33%) of the patients had
one or more orthopaedic surgical interventions at some
point of time. A total number of 280 surgical interven-
tions were ﬂagged in the database.
Baseline characteristics of both the groups (surgical vs
non-surgical) in the database were compared. The
patients who underwent surgeries had a mean age of
54.13±11.03 years (range=21–80 years) which was not
statistically different from the non-surgical group (53.73
±12.81 years (range=21–81 years); p=0.78). The gender
distribution was also not different between the surgical
and non-surgical groups (male/female=64.62%/35.38%
and 57.55%/41.73%, respectively; p=0.26; table 2). Of
note 54 (41.54%) patients who underwent surgery had a
single orthopaedic intervention while 76 (58.46%)
patients underwent multiple surgeries.
Effectively, of all the 280 surgeries, 193 (68.93%) took
place before the patients were included in the SPAR
database at the University Hospitals Leuven and 60
(21.42%) were performed after their inclusion in the
database. For the remaining 27 (9.64%), complete data
with exact dates of surgeries were not available in the
database. Interestingly, 179 (63.92%) of all these surger-
ies were performed after the diagnosis, whereas 101
(36.07%) were performed before these patients were
diagnosed with PsA (table 2). Among the surgeries per-
formed before diagnosis, 40.59% were arthroscopies
including 9.90% diagnostic arthroscopies.
Among the patients with PsA with surgeries, 49.23%
and 42.30% patients were treated with either anti-TNFα
medications±disease-modifying antirheumatic drugs
(DMARDs) or DMARDs only, respectively, whereas in
the non-surgical group, 39.56% and 47.48% patients on
anti-TNFα therapy±DMARDs and DMARDs only were
identiﬁed (p=0.11; p=0.39; table 2). We did not ﬁnd any
signiﬁcant difference between the two groups based on
their treatment.
A signiﬁcant difference in the mean HAQ 3 score
(representing the functional outcome) was observed
among the patients who underwent surgeries (0.95±0.82)
and those who did not undergo surgeries (0.59±0.68)
with p value of <0.001. For the patients who underwent
surgery, the mean disease duration±SD was 1.58 years
±12.05 at the time of surgery with a range of −35 to 31.
We did not ﬁnd any statistically signiﬁcant difference in
the mean age, mean disease duration and mean HAQ
score between the patients who underwent single surgery
and those who had multiple surgeries (p>0.05).
The details about the phenotype of PsA among the two
groups are shown in table 3. A signiﬁcant difference was
observed between the surgical and non-surgical group of
patients with asymmetric oligoarticular PsA and periph-
eral and axial form of PsA, with clearly more of these
patients in the surgical group, whereas least surgical
interventions were observed in the patients with unspeci-
ﬁed form of PsA. We did not ﬁnd any signiﬁcant differ-
ence among the rest of the PsA phenotypes (table 3).
The type of surgeries included both joint sacriﬁcing
and non-joint sacriﬁcing procedures with more of
Table 1 Characteristics of PsA patient population
Total patients with PsA 269
Age (mean±SD) 53.94±11.93
Male/female 164 (60.96%)/104
(38.66%)
Disease duration (mean±SD) 7.12±7.65
Positive family history of
psoriasis
133 (49.44%)
Positive family history of PsA 31 (11.52%)
ESR (mean±SD) 20.83±20.54
CRP (mean±SD) 15.04±23.19
Skin involvement 169 (62.82%)
Nail involvement 5 (1.86%)
Dactylitis 19 (7.06%)
Enthesitis 17 (6.31%)
PASI score (mean±SD) 1.77±5.05
CRP, C reactive protein; ESR, erythrocyte sedimentation rate;
PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis.
Table 2 Demographic data of the patients with PsA
PsA with surgeries PsA without surgeries p Value
Number of patients 130 (48.33%) 139 (51.67%) −
Males/females 84 (64.62%)/46 (35.38%) 80 (57.55%)/58 (41.73%) 0.26
Mean age (years)±SD 54.13±11.03 53.73±12.81 0.78
Mean HAQ 3 score±SD 0.95±0.82 0.59±0.68 <0.001
Number of patients currently on
TNF-α blockers±DMARDs 64 (49.23%) 55 (39.56%) 0.11
DMARDs 55 (42.30%) 66 (47.48%) 0.39
None 11 (8.46%) 18 (12.94%) 0.24
†Mann-Whitney U test.
DMARDs, disease-modifying antirheumatic drugs; PsA, psoriatic arthritis; TNF, tumour necrosis factor.
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the joint sacriﬁcing surgeries being performed in the
lower limbs as compared with the upper limbs (table 4).
For the joint sacriﬁcing surgeries, the recorded mean
age±SD of the patients at the time of surgery was
51.35 years±11.83 (range 30–75 years) Also the distribu-
tion of these surgeries among the different phenotypes
of PsA is shown in table 5 with the largest number of sur-
geries being performed in patients with asymmetric
monoarticular/oligoarticular arthritis including arthros-
copies, hip and knee surgeries, surgeries for CTS and
others. The subcategory of “others” in the non joint sac-
riﬁcing surgeries includes 62.50% of hand and foot sur-
geries and 37.50% of other surgeries.
DISCUSSION
This is the ﬁrst cross-sectional study on orthopaedic sur-
geries in patients with PsA conducted in the Belgian
population and also addresses this question in the bio-
logics era. In our study, the patients represent a full
spectrum of PsA with all types, disease durations, sever-
ity, treatments and age groups. To minimise the risk of
selection bias, all the patients with PsA who reported to
the Rheumatology Department of the University
Hospitals Leuven and gave informed consent were
included in the database. All the patients underwent
standard assessment and treatment at the hospital in a
dedicated PsA clinic managed by trained and experi-
enced rheumatologists with speciﬁc interest in the
disease. There is a risk for multiple testing. However,
this was an explorative study and no correction for mul-
tiple testing was therefore used. The results showed
that 48.33% of the patients with PsA required one or
the other surgical intervention at some point in time
out of which two-third of the surgeries were performed
after they had been diagnosed with PsA. This number
is much greater than the numbers reported by Zangger
et al who showed that only 7% of patients with PsA
required surgery once the diagnosis of PsA had been
established. In our cohort, we also found a much
shorter mean disease duration of 1.58±12.05 years at
the time of surgery with a range of −35 to 31 years as
compared with the mean disease duration of 13 years
(range=1–46 years) in an earlier report.16 Similarly as
compared with a study on patients with RA the,
number of surgical interventions increased in patients
with PsA even with a lower mean disease duration and
age as compared with the patients in the RA group
who had a mean disease duration of 8±6.9 years and
mean age of 57±12 years.21 Several factors could play a
role in these remarkable differences: (1) PsA is cur-
rently much more actively managed and referral to
surgery may therefore occur quicker than before; (2)
the road towards diagnosis and treatment may show
geographical and historical differences with referral pat-
terns for instance in case of monoarthritis being differ-
ent between countries and regions; and (3) local
settings may or may not facilitate the interactions with
orthopaedic surgeons. Our surgery prevalence numbers
could be inﬂuenced by the fact that this study was per-
formed in a centre with a secondary regional and ter-
tiary academic function.
Table 3 Types of PsA
Type of PsA
PsA with surgeries
n (%)
PsA without surgeries
n (%) p Value
Symmetric polyarthritis 32 (24.61%) 44 (31.65%) 0.20
Asymmetric mono/oligoarticular arthritis 46 (35.38%) 32 (23.02%) *0.02
Peripheral and axial 20 (15.38%) 4 (2.88%) *<0.001
Arthritis mutilans 2 (1.54%) 2 (1.44%) 0.94
Predominant spondylitis 8 (6.15%) 9 (6.47%) 0.91
Unspecified 22 (16.92%) 48 (35.53%) *0.001
Total patients with PsA 130 139
*Indicates a statistically significant p value.
PsA, psoriatic arthritis.
Table 4 Number of individual surgeries and mean
disease duration at which the surgery was performed
Type of surgery
Number of
patients
with PsA
n (%)
Mean
disease
duration at
the time of
surgery
(years)
Joint sacrificing surgeries
Ankle prosthesis 2 (0.71%) –
Arthrodesis 14 (5.00%) 4.53
Hip prosthesis 19 (6.79%) 5.53
Knee prosthesis 16 (5.71%) 7.73
Shoulder prosthesis 2 (0.71%) 7.66
Spine prosthesis/disc 1 (0.36%) –
Non-joint sacrificing surgeries
Arthroscopic synovectomy 22 (7.86%) 6.68
CTS 19 (6.79%) −1.61
Diagnostic arthroscopy 65 (23.21%) 3.45
Discectomy 13 (4.64%) −3.41
Meniscus operation/
arthroscopy
43 (15.36%) −7.5
Others 64 (22.86%) 2.49
Total number of surgeries 280
A negative value indicates surgeries performed before diagnosis.
CTS, carpal tunnel syndrome; PSA, psoriatic arthritis.
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Our study results also showed a signiﬁcant (p<0.001)
difference in the mean HAQ 3 score among the patients
who underwent orthopaedic surgical interventions and
those who did not, unlike Zangger et al16 who did not
ﬁnd any signiﬁcant difference among the two groups.
This appears to suggest that the impact of disease on
patients who require surgery is higher. We did not have
complete HAQ score data before and after the surgeries
as a large number of surgeries were performed before
inclusion in the SPAR database. We therefore used the
HAQ score for all the patients recorded on the last visit
to compare the current status and long-term impact of
surgical interventions on patient’s quality of life.
As shown in the previous studies in the literature, our
data also suggest that among all the joint sacriﬁcing sur-
geries performed on the patients with PsA, hip and
knee surgeries were the most common procedures
required in the management of patients with PsA.16 17
This consistent observation emphasises the functional
impact of large joint involvement in this patient popula-
tion and suggests the need for a tailored and aggressive
management of disease in large joints. Taking into
account that the mean age of the patients who under-
went these joint replacement surgeries was relatively
young (51.35±11.38 SD), we do not consider osteoarth-
ritis as a main factor for the joint damage.
Unlike the previous studies in the literature, we also
tried to see if different phenotypes of PsA behave differ-
ently and discovered that the patients with asymmetric
oligoarticular arthritis had the most number of surgeries
followed by symmetric polyarthritis and an unspeciﬁed
form.17 18 This could also be an indicator that certain
forms of PsA are more likely to undergo a surgical inter-
vention as compared with the other forms and should
be monitored closely for any radiographic changes or
joint damage to reduce the risk of surgeries in these
patients. There were a lot of surgeries performed before
the patients were initially diagnosed with PsA and a
large number of these include diagnostic arthroscopies
and CTS. This is potentially an indicator of delay in diag-
nosis and treatment and can also be a reason for ﬁnding
the high rate of surgical interventions and poor HAQ 3
score in our patients group. Haroon et al22 showed that
diagnostic delay of just 6 months leads to increased risk
of joint erosions and poor long-term physical function
outcomes and quality of life. This underlines the need
for early diagnosis and referral to a rheumatologist and
aggressive management of PsA from the very beginning
to slow down the disease progression and improve the
quality of life in these patients.
We did not ﬁnd any statistically signiﬁcant difference
between the surgical and non-surgical groups based on
their treatment. This could be due to some patient selec-
tion as the impact of mechanical factor on pain in a
damaged joint may inﬂuence the decision-making
process when starting biological therapy. Although
anti-TNFα medications have shown to be more effective
in controlling peripheral and axial disease,23 we still
found higher prevalence of peripheral and axial disease
in the surgical group as compared with the non-surgical
group (table 3). The treatment paradigms in PsA are
rapidly changing and our results represent the current
treatment status of the patients. We do not have com-
plete presurgical and postsurgical treatment data as
almost 69% of the surgeries were performed before the
patients were included in the SPAR cohort, and we lack
details about prior treatment. So due to this limitation,
we would not wish to comment further on the effect of
therapy in the prevention of joint damage.
CONCLUSION
There are more number of surgical interventions in our
PsA patient cohort as compared with historic ﬁgures
Table 5 Distribution of different types of surgeries among the various phenotypes of PsA
Types of surgery
Peripheral
and axial
n=20
Symmetric
polyarthritis
n=32
Asymmetric
oligoarticular
arthritis
n=46
Arthritis
mutilans
n=2
Predominant
spondylitis
n=8
Unspecified
n=22
Meniscus operation/arthroscopy 14 10 17 0 0 2
Diagnostic arthroscopy 8 19 28 0 4 6
Others 12 19 17 2 3 11
Hip prosthesis 4 6 3 0 6 0
Discectomy 2 7 4 0 0 0
Arthroscopic synovectomy 2 5 9 0 0 6
Knee prosthesis 2 4 6 0 1 3
Arthrodese 4 5 4 0 1 0
Shoulder prosthesis 0 1 1 0 0 0
CTS 0 4 10 0 1 4
Spine prosthesis disc 0 1 0 0 0 0
Ankle prosthesis 0 0 1 0 1 0
Total number of surgeries 48 81 100 2 17 32
CTS, carpal tunnel syndrome; PSA, psoriatic arthritis.
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reported in patients with PsA and RA even with a lower
mean disease duration. There was a signiﬁcant differ-
ence in HAQ scores between patients who underwent
surgery or did not undergo surgery. Of interest, 36.07%
of the orthopaedic interventions were performed before
diagnosis including 9.90% of diagnostic arthroscopies
indicating a potential delay in diagnosis. The study
results indicate that prevention of skeletal damage and
the need for surgical interventions is important in
patients with PsA. Early diagnosis and aggressive man-
agement of PsA from the very beginning to slow down
the disease progression may reduce the risk of surgical
interventions and provide an opportunity to improve the
quality of life in these patients.
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